C
OMBINED BILATERAL lung and liver transplantation (CLLT) may be a treatment option for patients with endstage lung disease and impaired liver function when they are not expected to survive with either transplantation alone. 1, 2 Cystic fibrosis (CF), as well as alpha-1 antitrypsin deficiency or portopulmonary hypertension, which can affect both lung and liver, may be possible indications for CLLT. 3, 4 Because of the absence of randomized controlled trials on CLLT and the overall paucity of clinical data regarding this particular intervention, no recommendations for the anesthetic management during CLLT and, more specifically, for the use of mechanical circulatory support have been published to date. In fact, most cases are reported by cardiac/thoracic surgeons, and transplantation centers presumably act according to selfestablished protocols. Cardiopulmonary bypass (CPB) during CLLT often is used 1,4-7 but is not mandatory. 3, 8, 9 The use of CPB during CLLT also has been reported inconsistently. 2, 10 To the best of the authors' knowledge, extracorporeal membrane oxygenation (ECMO) thus far has not been reported to be operated during CLLT. Consequently, this case report showed for the first time, that CLLT could be performed successfully with intraoperative ECMO. Moreover, an overview of the published data on CLLT with regard to mechanical circulatory support is provided and whether ECMO may be an alternative to implementation of CPB with full heparinization for this intervention is discussed.
Written informed consent was obtained from the patient before submission and publication of this case.
CASE REPORT
A 24-year-old Caucasian man (height, 177 cm; weight 51 kg; body mass index: 16.3 kg/m 2 ; lung allocation score: 52), American Society of Anesthesiologists physical status IV, with CF was scheduled for CLLT. His past medical history included severe end-stage obstructive lung disease (forced expired volume in 1 second: 0.79 L; pulmonary vital capacity: 20% of predicted) and mild pulmonary hypertension (mean pulmonary artery blood pressure [mPAP]: 32 mmHg). The patient also presented with liver cirrhosis Child A and portal hypertension, esophageal varices III1, and hypersplenism with thrombocytopenia (model for end-stage liver disease score 9). Other comorbidities included insulin-dependent diabetes mellitus and osteopenia. The preoperative assessment is recorded in Table 1 . In an interdisciplinary approach with thoracic, cardiac, and visceral surgeons as well as anesthesiologists it was agreed to begin with the lung transplantation followed by the liver transplantation. Moreover, veno-arterial (va)-ECMO, rather than CPB, was to be instituted, but only in case of surgical difficulties, primary graft dysfunction (PGD), hypoxia, or right heart failure with pulmonary hypertension. This case report is divided into 6 distinct phases, as follows.
PHASE I: ANESTHESIA INDUCTION
Induction of anesthesia was performed according to the standard operating procedure for lung transplantation at the authors' institution. Under local anesthesia, a 20G arterial cannula was placed in the left radial artery. After sufficient preoxygenation, general anesthesia was induced with 40 mg of sufentanil, 150 mg of propofol, and 5 mg of midazolam via intravenous (IV) access on the left forearm. After neuromuscular blockade with 50 mg of rocuronium, a left-sided double-lumen endotracheal tube was placed (39 Charrière, Cormack/Lehane 1I). Total IV anesthesia was maintained with sufentanil (1 mg/kg/h) and propofol (6-8 mg/kg/h). Inspiratory oxygen fraction (FIO 2 ) was kept at 1.0. Maximum inspiratory pressure, positive endexpiratory pressure (PEEP), and respiratory rate were adjusted according to arterial blood gas analyses to avoid excessive acidosis. Hemodynamic management included continuous infusions of norepinephrine (maximum 0.23 mg/kg/ min) and epinephrine (maximum 0.1 mg/kg/min) aimed at maintaining mean arterial blood pressure (MAP) above 60 mmHg.
Neuromuscular blockade with rocuronium (1 mg/kg) was repeated when needed. Two 12G dialysis catheters were inserted into the right internal jugular vein and the right femoral vein, respectively. A 7F pulmonary artery catheter (PAC) was placed via an 8F introducer into the right internal jugular vein. Hemodynamic monitoring including measurement of cardiac output was performed via CCOmbo-PAC (CI-Vigilance, Edwards Lifesciences Corporation, Unterschleissheim, Germany) after in vivo calibration using the commercially available Vigilance II monitor (Edwards Lifesciences Corporation, Unterschleissheim, Germany). Finally, a 12G gastric tube and a 14G bladder catheter were inserted. Antibacterial coverage was provided by repetitive doses of meropenem (in total 2 g). Antifibrinolysis was established with a single dose of tranexamic acid (2.5 g). A 17F cannula for venovenous bypass during liver transplantation were placed into the left femoral vein by the liver surgeons.
PHASE II: TRANSPLANTATION OF THE RIGHT LUNG
Lung transplantation was performed via clamshell incision starting with the right lung. Because of recurrent pulmonary infections, explantation of the lungs and reimplantation of the donor lungs was extremely difficult. Hemodynamic stability (MAP higher than 60 mmHg) was maintained throughout transplantation of the right lung by norepinephrine and epinephrine. In this phase of the intervention, the lowest cardiac output recorded was 2.1 L/min with concomitant ejection fraction of 15% ( Table 2) . As mPAP increased to 46 mmHg after clamping of the right pulmonary artery, therapy with inhaled nitric oxide (NO, 5 parts per million) was initiated. Activated clotting time (ACT) was 113 seconds (Table 3) . Clamping time of the right pulmonary artery was 90 minutes and cold ischemic time of the right lung was 5 hours and 35 minutes. Toward the end of the transplantation of the right lung, 20 mg of inhaled iloprost were given once to combat mPAP rising to 42 mmHg. With decreasing mPAP, NO was discontinued. Because of persisting anuria, continuous renal replacement therapy (hemodiafiltration; Multifiltrate, Fresenius Medical Care, Bad Homburg, Germany) was initiated via the right femoral vein.
PHASE III: TRANSPLANTATION OF THE LEFT LUNG
Transplantation of the left lung was carried out shortly after declamping of the right pulmonary artery. Administration of norepinephrine and epinephrine was continued to maintain hemodynamic stability. When mPAP increased to 49 mmHg about 10 minutes after clamping of the left pulmonary artery, continuous administration of milrinone was started at 0.33 mg/kg/ min. When the need for vasopressors increased considerably (norepinephrine, 0.5 mg/kg/min, epinephrine, 0.16 mg/kg/min), vasopressin was started at 0.02 U/kg/h and milrinone infusion rate reduced to 0.06 mg/kg/min. In this phase of the intervention, the lowest cardiac output recorded was 5.6 L/min with concomitant ejection fraction of 27% (Table 2) . ACT was 115 seconds (Table 3) . Multiplate (Roche Diagnostics, Mannheim, Germany) testing showed regular platelet function. Clamping time of the left pulmonary artery was 87 minutes and cold ischemic time of the left lung was 7 hours and 16 minutes. After reperfusion of the left lung, oxygenation was severely impaired (PaO 2 /FIO 2 ratio o100 mmHg) because of PGD. Accordingly, central va-ECMO treatment was established before liver transplantation.
PHASE IV: ECMO IMPLANTATION
Before the intervention, it had been decided to establish va-ECMO treatment without heparinization. Central va-ECMO was placed by cannulation of the aorta (20G cannula) and the right atrium (32G cannula). ECMO blood flow was run at 4-5 L/min with sweep gas flow rate (FIO 2 ¼ 1.0) adjusted to maintain arterial pCO 2 between 50 and 65 mmHg. Antimicrobial coverage was provided by a single dose of vancomycin (500 mg) followed by continuous infusion of vancomycin (500 mg/h), totaling 1 g of vancomycin.
PHASE V: LIVER TRANSPLANTATION
Orthotopic liver transplantation was performed while under va-ECMO using venovenous bypass (liver implantation time: 2 hours and 26 minutes; cold ischemic time of the liver: 10 hours and 29 minutes). The patient's hemodynamic parameters remained stable throughout liver transplantation. While still on venovenous bypass, va-ECMO blood flow was hampered considerably during partial clamping of the inferior vena cava, which was necessary for vascular anastomosis in a "piggyback" technique. Therefore, ECMO blood flow had to be reduced to 1.5 L/min. The ACT was 97 seconds (Table 3) . To avoid thromboembolic complications as a result of low ECMO blood flow, the first IV bolus of heparin (3,500 IU) was administered. Again, Multiplate testing showed regular platelet function. After reperfusion of the vena cava, mPAP rose from 16 to 40 mmHg, and 20 mg of inhaled iloprost were administered twice. The ACT was 107 seconds, and a second IV bolus of heparin (1500 IU) was administered.
Transfusion requirements including mechanical autotransfusion (Cell Saver, Fresenius, Bad Homburg, Germany) during the perioperative phases of CLLT are recorded in Table 3 .
PHASE VI: POSTOPERATIVE CARE
Finally, the patient was transferred to the intensive care unit (ICU) with central va-ECMO in place because of persistent reperfusion edema and impaired oxygenation. After initial stabilization, the patient underwent rethoracotomy for surgical bleeding on postoperative day (POD) 1 and was packed with abdominal cloths while still under va-ECMO coverage. On POD 2, abdominal cloths were removed and the patient was weaned successfully from va-ECMO. The patient was extubated on POD 5 and transferred to the ward on POD 30 after removal of a rightsided thoracic hematoma on POD 23. Transfusion requirements during postoperative care are documented in Table 3 . Perfusion and function of both transplanted organs never were impaired. Until discharge from the hospital, no neurologic deficit was recorded. One year after the transplantation, the patient had excellent physical and mental status.
DISCUSSION
The perioperative management of a patient with CF is reported, thus introducing ECMO treatment in the context of CLLT. In this report, the authors distinguished 6 different phases during CLLT: (1) the induction period, (2) 
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transplantation of the right lung, (3) transplantation of the left lung, (4) initiation of central va-ECMO, (5) orthotopic liver transplantation, and (6) the postoperative period. Of note, ECMO treatment was initiated after having completed sequential bilateral lung transplantation.
Several case reports and small series exist concerning combined bilateral lung and liver transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, detailed reports on the interdisciplinary reasoning regarding the type of mechanical circulatory support currently are not available. Thus far, CPB remains the only device to be successfully used during CLLT.
In addition, the order of the transplantation procedure is crucial, because lung and liver differ considerably in the respective ventilation and fluid management. 6, 11, 12 With the exception of a recently published case on reversed transplant procedure in which the liver was transplanted first, 13 CLLT commonly is performed by was transplanting the lung first, followed by the liver. Reasoning behind this order includes the presumed inability of the patient's lungs to withstand the administration of large quantities of intravascular fluids associated with orthotopic liver transplantation. Moreover, impaired coagulation in case of liver graft dysfunction would hamper subsequent bilateral lung transplantation. Consequently, the authors transplanted the lungs first followed by the liver. The risk of pulmonary PGD, however, must not be ignored, as was observed in this case. Prolonged ischemic times contribute to PGD and are to be avoided. 14 In the present case, ischemic times for both lungs were in accordance with recently published ischemic times in bilateral lung transplantation. 15 Nevertheless, pulmonary PGD forced the authors to initiate extracorporeal support before liver transplantation.
In liver transplantation, CPB represents a rescue option in severe postreperfusion syndrome. 16 Although ECMO frequently is used before or after liver transplantation, initiation of ECMO therapy during the liver transplantation procedure remains exceptional. 17, 18 In lung transplantation, extracorporeal circulatory support may be used in selected patients to avoid excessive pulmonary hypertension and associated right heart failure, global hypoxia and hemodynamic instability.
19 Classically, conventional CPB has been used in these situations 20 but concerns have long been raised. 21 Recently, the use of ECMO devices with low-dose heparinization increasingly has been reported to reduce perioperative morbidity in lung transplantation. Several transplantation centers reported markedly lower transfusion requirements, postoperative ventilator times, and ICU stays in ECMO-supported lung transplants when compared with CPB-supported procedures.
15,22-25 Moreover, intraoperative ECMO can be used effectively for the treatment of PGD 26 resulting from hypoxia, increased pulmonary hypertension, as well as right heart failure. 27 Consequently, the Munich Lung Transplant Group has implemented ECMO therapy as the standard of care for extracorporeal circulatory support in lung transplantation. Accordingly, the use of CPB during lung transplantation is restricted to complicated cases with concomitant intracardiac repairs. In contrast, CPB is the only extracorporeal circulatory device that has been used successfully during CLLT. Consequently, the authors' institutional standard operating procedure for ECMO usage in lung transplantation could not be transferred uncritically to this CLLT procedure, simply because CLLT must not be reduced to 2 distinct surgical procedures performed sequentially. Although the initial bilateral lung transplant may be performed in a "routine" fashion, relevant hemodynamic alterations and associated effects of the reperfused lungs are to be expected during the subsequent liver transplantation. For example, reperfusion of the liver may lead to increased cardiac output with high risk of pulmonary shunting, pulmonary hypertension, and right heart failure resulting in pulmonary edema. 7, 28 Consequently, the thoracic cavity was accessed via clamshell incision, although the authors consider bilateral anterolateral thoracotomy the standard for double-lung transplantation. This was done to obtain the best possible access and control over the thoracic cavity. Most importantly, however, the authors implemented central cannulation for the ECMO device, achieving optimal unloading of the pulmonary circulation, thus minimizing intraoperative ventilator support. Therefore, liver reperfusion did not represent a major challenge to the implanted pulmonary graft. Peripheral va-ECMO cannulation via the femoral blood vessels would not have been as efficient as central cannulation. In addition, the right femoral vein contained a dialysis catheter and the left femoral vein was to be cannulated for venovenous bypass during liver transplantation. Implementation of venovenous ECMO would not have relieved the right ventricle sufficiently and, therefore, was never taken into consideration.
It cannot be concluded from this case report that CLLT always should be performed with extracorporeal circulatory support. The use of an extracorporeal assist device will be inevitable in case of refractory hemodynamic instability. In patients with transient right heart insufficiency, intraoperative ECMO therapy with low-dose heparin may represent a promising alternative to CPB with full heparinization, because it is easy to install and to operate. In addition, intraoperative ECMO does not have to be weaned at the end of surgery but may be transferred with the patient to the ICU, where it can be operated safely by ICU staff.
The authors acknowledge that the patient did suffer from severe on POD 1 requiring rethoracotomy on the same day. However, 2 heparin boluses (5,000 IU in total) had to be given during liver transplantation to prevent ECMO clotting after low ECMO blood flow, which might have accounted for the massive transfusion on POD 1 and the prolonged stay in the ICU. However, point-of-care analyses before each heparin bolus showed a low ACT. In addition, ECMO was weaned successfully on POD 2 and the patient was extubated on POD 5, which was in accord with recently published data using va-ECMO in bilateral lung transplantation. The time and criteria to initiate intraoperative ECMO during CLLT remain to be determined. Because ventilator settings were at the limit of lung protective ventilation and mPAP values showed a significant increase over baseline during the bilateral lung transplantation (Table 2) , the patient might have already been eligible for va-ECMO. Yet, at this point inhaled NO and iloprost therapy considerably decreased mPAP. In addition, the patient was hemodynamically stable regarding vasopressor therapy and inotropic support. Moreover, mPAP decreased after inhaled iloprost therapy and did not rise excessively after clamping of the pulmonary artery.
Consequently, the decision between anesthesiologists and surgeons was not to initiate va-ECMO therapy during the lung transplantation procedures. However, the patient developed PGD grade III before liver transplantation had even started, thus triggering extracorporeal circulatory support. In retrospect, the authors acknowledge that ECMO therapy may have been initiated too late, because the patient developed pulmonary reperfusion edema immediately after sequential double-lung transplantation. As a consequence, va-ECMO could have been implemented when either ventilator settings exceeded the limits of lung protective ventilation or mPAP values increased considerably over baseline, or at the end of lung transplantation at the latest to prevent pulmonary PGD.
With regard to monitoring the patient's cardiac output, PAC placement is the authors' clinical standard for both single and bilateral lung transplantation, as well as for liver transplantation. Although rarely mentioned explicitly, 4,6,9 monitoring cardiac output and mPAP by pulmonary artery catheterization may be considered mandatory because both pulmonary hypertension and PGD can occur intraoperatively 7 or in the immediate postoperative period after lung transplantation. Furthermore, liver transplantation often is associated with arterial hypotension. The use of transesophageal echocardiography (TEE) can provide additional information in differentiating hemodynamic changes 4 and also may be used in patients undergoing orthotopic liver transplantation. 30 Considering the patient's esophageal varices and the necessity to place a PAC to monitor mPAP, monitoring cardiac output continuously with the CCOmbo-PAC was preferred and a TEE probe was not used.
In cases of pulmonary hypertension after induction of anesthesia and PAC placement, a conservative treatment approach with inhaled NO and/or iloprost, as well as IV milrinone may be undertaken. Although a recent metaanalysis has shown that inhaled NO may result in only limited improvement mortality benefit in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), 31 NO has been shown to increase right ventricular ejection fraction and to decrease right end-systolic volume, thus preventing decompensation of acute cor pulmonale. 32 Therefore, NO may be used, 33 but remains a rescue therapy in severe hypoxemia, possibly decreasing the need for extracorporeal circulatory support.
The authors adopted the intraoperative ventilation management during this CLLT from strategies originating from lung transplantation. 34 Recommendations on mechanical ventilation techniques during lung transplantation are derived from studies focusing on ALI and ARDS because ALI, ARDS, and PGD may be considered related entities. 34 ALI can result from peak inspiratory pressures with high tidal volumes during mechanical ventilation. 35 Consequently, mechanical ventilation with low tidal volumes has been accepted as standard practice in patients with ARDS and also has been shown to reduce morbidity and mortality in non-ARDS patients.
36,37 Because lung and combined lung and liver transplant patients are at high risk of developing PGD, it can be postulated that a similar ventilation strategy may be protective for the newly implanted donor lung in lung transplantation and CLLT. The necessity of lung protective ventilation has only been recommended for lung transplantation 38 and not explicitly for CLLT. Yet, a combination of ventilation strategies incorporating a low tidal volume (less than 6 mL/kg), moderate PEEP, and maximum inspiratory pressure of less than 20 cm H 2 O above PEEP, appears to be beneficial in lung transplantation 34 and also potentially in CLLT.
In summary, the authors presented a case of CLLT in a patient with CF. After sequential bilateral lung transplantation, extensive pulmonary reperfusion edema with subsequent right heart insufficiency triggered the need for an extracorporeal cardiopulmonary assist device. Accordingly, central va-ECMO therapy was initiated and operated throughout the end of the transplantation well into the ICU stay. Va-ECMO was weaned successfully after 2 days. Although extensive blood transfusion and rethoracotomy were required in the prolonged stay in the ICU, lung and liver function never were impaired. Moreover, the patient did not present any neurologic deficit before discharge from the hospital. This report showed that extracorporeal circulatory support by ECMO could be performed safely and with excellent outcome in CLLT. Therefore, this promising result may encourage the use of ECMO instead of CPB during CLLT.
